More Topics:
PAREXEL to Address Innovative Approaches to Late Stage Development at Summit for Clinical Ops Executives
Posted February 6, 2012
We Recommend...
Company to Chair Session on Electronic Health Records and Clinical Trials, Discuss Social Media in Patient Recruitment
BOSTON, -- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that Ramita Tandon, Global Head, Late Phase Clinical Trials and Lars-Olof Eriksson, Ph.D., MS.c., Vice President, Global Research Operations at PAREXEL will address innovative approaches to late stage development at the Summit for Clinical Ops Executives (SCOPE), to be held February 7-9, 2012 in Miami, Florida. Attendees can learn about customized strategic and scientific solutions, provided by the PAREXEL PACETM (Peri-Approval Clinical Excellence) group, to facilitate the transition from product development to commercialization in a seamless and cost-effective manner, by visiting the PAREXEL Booth #38 on the exhibit floor.
During SCOPE, Ms. Tandon will provide opening remarks for the session entitled "Electronic Health Records and Clinical Trials." The session, which will be held on Tuesday, February 7 at 8:15 a.m., includes presentations from Pfizer, Incyte Corporation, and the Medicines and Healthcare products Regulatory Agency (MHRA).
Other program sessions being presented by PAREXEL experts include:
Tuesday, February 7, 4:30 p.m. and Wednesday, February 8, 4:20 p.m.
• "New Challenges Call for Innovative Approaches to Patient Recruitment and Retention for Post Marketing Trials," in two interactive breakout discussion groups
Facilitated by Ms. Tandon and Dr. Eriksson, these interactive discussions will assist attendees in understanding how effective strategies for emerging areas, including engagement in social media and use of electronic medical records, can offer benefits to the post marketing research enterprise and patient community. They will highlight trends driving the need for cost efficient patient recruitment and retention approaches.
Wednesday, February 8, 11:35 a.m.
• "Conducting Phase IIIB/IV Clinical Trials in a Changing Drug Environment," in the session Utilization of Patient-Level Data and Patient Reported Outcomes in Trials
Ms. Tandon will discuss industry dynamics that have placed increasing emphasis on the use of late phase clinical trial data. She will examine innovative and cost efficient tools and methodologies to conduct post marketing trials to ensure higher data quality, and accelerate better decision-making.
PAREXEL's late phase capabilities include Phase IIIb and IV clinical trials, observational research, post approval safety surveillance programs and post-marketing pharmacovigilance, as well as health economics and outcomes research services. For more information, visit:
http://www.PAREXEL.com/services-and-capabilit....
About PAREXEL International
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has approximately 11,300 employees. For more information about PAREXEL International visit www.PAREXEL.com.
blog comments powered by